医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Renesas Electronics Creates Open-Source Ventilator System Reference Design to Fight COVID-19 Pandemic

2020年04月16日 PM09:00
このエントリーをはてなブックマークに追加


 

TOKYO

Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today introduced a new open-source ventilator system reference design that customers can use to swiftly design ready-to-assemble boards for medical ventilators. Many regions are experiencing a critical shortage of ventilators as COVID-19 infections continue to rise and hospital demand exceeds supply.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005169/en/

Renesas helps designers address COVID-19 pandemic by providing new reference design for ventilator systems (Graphic: Business Wire)

Renesas helps designers address COVID-19 pandemic by providing new reference design for ventilator systems (Graphic: Business Wire)

“Renesas’ engineers have created a ventilator system reference design to address the challenges our global community faces as we fight the COVID-19 pandemic,” said Chris Allexandre, Senior Vice President, IoT and Infrastructure Business Unit at Renesas. “Leveraging our broad product portfolio and system design expertise, we are enabling customers to accelerate their development of medical ventilator systems capable of operating in a home or hospital environment.”

Renesas’ engineers have followed several open-source ventilator designs, including the Medtronic PB560, to come up with an easy to assemble three board ventilator design. It controls the tidal volume and mixture of gas delivered to the patient while monitoring the patient’s status. The ventilator is portable and can be used with or without gas tanks. In addition, a humidifier can be connected to the ventilator’s intake path to soothe the patient’s breathing, making it more comfortable to be connected for long durations.

The reference design uses 20 Renesas ICs, consisting of microcontroller (MCU), power, and analog ICs that address many of the ventilator’s signal chain electrical functions. The system design implements a sensor board, a motor control board, and features Bluetooth® connectivity that allows medical professionals to monitor several patients simultaneously via a tablet or other mobile device. Each board has a microcontroller (MCU) to control its specific task while monitoring the status of the connecting board. The ventilator solution also provides a system of checks and balances to enable regulatory approval and provide patient safety.

For more information, please visit: Renesas ventilator system reference design.

Renesas is committed to developing innovative solutions that address the challenges our customers face. Learn more about the Renesas solutions used in equipment critical for fighting the life-threatening coronavirus: www.renesas.com/about/press-center/covid-19.

About Renesas Electronics Corporation

Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, home electronics, office automation, and information communication technology applications that help shape a limitless future. Learn more at renesas.com.

(Remarks). All names of products or services mentioned in this press release are trademarks or registered trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005169/en/

CONTACT

Media Contacts:

Americas

Mark Alden

Renesas Electronics Corporation

+ 1-408-546-3402

mark.alden.eb@renesas.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)